Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 13/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943287 | 0.92 | CMA1 (0.69) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL942384 | 0.87 | CMA1 (0.59) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL941826 | 0.85 | CMA1 (0.67) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL943095 | 0.85 | CMA1 (0.56) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL942504 | 0.82 | CMA1 (0.83) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL945311 | 0.82 | CMA1 (0.65) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL941590 | 0.80 | CMA1 (0.64) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL943229 | 0.79 | CMA1 (0.62) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL943753 | 0.79 | CMA1 (0.44) | CMA1RAB9ANPC1POLBSMN1; SMN2 | |
| SCHEMBL944662 | 0.78 | CMA1 (0.69) | CMA1PRSS1PRSS2CTSGPRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872044-B2 | (thio)amide benzofuran compounds containing phosphonic, phosphinic, sulfonic, sulfamic, or carboxy acid groups; for example [benzofuran-3-yl-(naphthalen-2-ylcarbamoyl)-methyl]-phosphonic acid; treating inflammatory or serine protease mediated disorders such as allergic rhinitis, asthma and heart failure | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-18 | — | — | US | claimed |
| EP-2097399-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-09 | — | — | EP | claimed |
| US-20080096844-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | claimed |
| WO-2008048668-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | WO | claimed |
| US-7872044-B2 | (thio)amide benzofuran compounds containing phosphonic, phosphinic, sulfonic, sulfamic, or carboxy acid groups; for example [benzofuran-3-yl-(naphthalen-2-ylcarbamoyl)-methyl]-phosphonic acid; treating inflammatory or serine protease mediated disorders such as allergic rhinitis, asthma and heart failure | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-18 | — | — | US | disclosed |
| US-7872044-B2 | (thio)amide benzofuran compounds containing phosphonic, phosphinic, sulfonic, sulfamic, or carboxy acid groups; for example [benzofuran-3-yl-(naphthalen-2-ylcarbamoyl)-methyl]-phosphonic acid; treating inflammatory or serine protease mediated disorders such as allergic rhinitis, asthma and heart failure | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-18 | — | — | US | disclosed |
| EP-2097399-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-09 | — | — | EP | disclosed |
| US-20080096844-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096844-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096844-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| WO-2008048668-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096844-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, PRSS1 | CMA1 1/4885PRSS1 3/4885PRSS2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.